Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

PI3 kinase inhibitors in the clinic: an update.

Kurtz JE, Ray-Coquard I.

Anticancer Res. 2012 Jul;32(7):2463-70. Review.

PMID:
22753702
2.

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Wu P, Hu YZ.

Curr Med Chem. 2010;17(35):4326-41. Review.

PMID:
20939811
3.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C.

Mol Cancer Ther. 2008 Jul;7(7):1851-63. doi: 10.1158/1535-7163.MCT-08-0017. Epub 2008 Jul 7.

5.

Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.

Baselga J.

Oncologist. 2011;16 Suppl 1:12-9. doi: 10.1634/theoncologist.2011-S1-12. Review.

6.

New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.

Myers AP.

Clin Cancer Res. 2013 Oct 1;19(19):5264-74. doi: 10.1158/1078-0432.CCR-13-0615. Review.

7.

Present and future of PI3K pathway inhibition in cancer: perspectives and limitations.

Ciraolo E, Morello F, Hirsch E.

Curr Med Chem. 2011;18(18):2674-85. Review.

PMID:
21649577
8.

Recent developments of small molecule PI3K/mTOR dual inhibitors.

Liu YN, Wan RZ, Liu ZP.

Mini Rev Med Chem. 2013 Dec;13(14):2047-59. Review.

PMID:
24195664
9.

Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.

Bruce I, Akhlaq M, Bloomfield GC, Budd E, Cox B, Cuenoud B, Finan P, Gedeck P, Hatto J, Hayler JF, Head D, Keller T, Kirman L, Leblanc C, Le Grand D, McCarthy C, O'Connor D, Owen C, Oza MS, Pilgrim G, Press NE, Sviridenko L, Whitehead L.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5445-50. doi: 10.1016/j.bmcl.2012.07.042. Epub 2012 Jul 17.

PMID:
22863202
10.

ATP-competitive inhibitors of mTOR: an update.

Schenone S, Brullo C, Musumeci F, Radi M, Botta M.

Curr Med Chem. 2011;18(20):2995-3014. Review.

PMID:
21651476
11.

Advances in development of phosphatidylinositol 3-kinase inhibitors.

Kong D, Yamori T.

Curr Med Chem. 2009;16(22):2839-54. Review.

PMID:
19689267
12.

Novel benzofuran-3-one indole inhibitors of PI3 kinase-alpha and the mammalian target of rapamycin: hit to lead studies.

Bursavich MG, Brooijmans N, Feldberg L, Hollander I, Kim S, Lombardi S, Park K, Mallon R, Gilbert AM.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2586-90. doi: 10.1016/j.bmcl.2010.02.082. Epub 2010 Feb 23.

PMID:
20303263
13.

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.

Granville CA, Memmott RM, Gills JJ, Dennis PA.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89. Review.

14.

PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.

Goc A, Al-Husein B, Kochuparambil ST, Liu J, Heston WW, Somanath PR.

Int J Oncol. 2011 Jan;38(1):267-77.

PMID:
21109949
15.

4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.

Liu KK, Bagrodia S, Bailey S, Cheng H, Chen H, Gao L, Greasley S, Hoffman JE, Hu Q, Johnson TO, Knighton D, Liu Z, Marx MA, Nambu MD, Ninkovic S, Pascual B, Rafidi K, Rodgers CM, Smith GL, Sun S, Wang H, Yang A, Yuan J, Zou A.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):6096-9. doi: 10.1016/j.bmcl.2010.08.045. Epub 2010 Aug 14.

PMID:
20817449
16.

PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.

Brachmann S, Fritsch C, Maira SM, García-Echeverría C.

Curr Opin Cell Biol. 2009 Apr;21(2):194-8. doi: 10.1016/j.ceb.2008.12.011. Epub 2009 Feb 7. Review.

PMID:
19201591
17.

Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors.

Lin S, Han F, Liu P, Tao J, Zhong X, Liu X, Yi C, Xu H.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):790-3. doi: 10.1016/j.bmcl.2013.12.112. Epub 2014 Jan 3.

PMID:
24433860
18.

Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.

Ayral-Kaloustian S, Gu J, Lucas J, Cinque M, Gaydos C, Zask A, Chaudhary I, Wang J, Di L, Young M, Ruppen M, Mansour TS, Gibbons JJ, Yu K.

J Med Chem. 2010 Jan 14;53(1):452-9. doi: 10.1021/jm901427g.

PMID:
19928864
19.

[PI3K-AKT-mTOR pathway inhibitors].

Cortot A, Armand JP, Soria JC.

Bull Cancer. 2006 Jan;93(1):19-26. Review. French.

20.

The biology behind mTOR inhibition in sarcoma.

Wan X, Helman LJ.

Oncologist. 2007 Aug;12(8):1007-18. Review.

Supplemental Content

Support Center